Venus Medtech Stock Performance
| VMTHF Stock | USD 0.27 0.00 0.00% |
The entity has a beta of 0.2, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Venus Medtech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Venus Medtech is expected to be smaller as well. At this point, Venus Medtech has a negative expected return of -0.21%. Please make sure to validate Venus Medtech's treynor ratio and rate of daily change , to decide if Venus Medtech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Venus Medtech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's technical indicators remain nearly stable which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 2.7 B | |
| Total Cashflows From Investing Activities | -653 M |
Venus |
Venus Medtech Relative Risk vs. Return Landscape
If you would invest 31.00 in Venus Medtech on November 9, 2025 and sell it today you would lose (4.00) from holding Venus Medtech or give up 12.9% of portfolio value over 90 days. Venus Medtech is currently producing negative expected returns and takes up 1.3073% volatility of returns over 90 trading days. Put another way, 11% of traded pink sheets are less volatile than Venus, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Venus Medtech Target Price Odds to finish over Current Price
The tendency of Venus Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.27 | 90 days | 0.27 | about 72.42 |
Based on a normal probability distribution, the odds of Venus Medtech to move above the current price in 90 days from now is about 72.42 (This Venus Medtech probability density function shows the probability of Venus Pink Sheet to fall within a particular range of prices over 90 days) .
Venus Medtech Price Density |
| Price |
Predictive Modules for Venus Medtech
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Venus Medtech. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Venus Medtech Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Venus Medtech is not an exception. The market had few large corrections towards the Venus Medtech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Venus Medtech, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Venus Medtech within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.23 | |
β | Beta against Dow Jones | 0.20 | |
σ | Overall volatility | 0.02 | |
Ir | Information ratio | -0.23 |
Venus Medtech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Venus Medtech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Venus Medtech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Venus Medtech generated a negative expected return over the last 90 days | |
| Venus Medtech has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 415.86 M. Net Loss for the year was (373.64 M) with profit before overhead, payroll, taxes, and interest of 324.34 M. | |
| Venus Medtech has accumulated about 2.96 B in cash with (456.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.75, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 22.0% of the company outstanding shares are owned by insiders |
Venus Medtech Fundamentals Growth
Venus Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Venus Medtech, and Venus Medtech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Venus Pink Sheet performance.
| Return On Equity | -0.11 | |||
| Return On Asset | -0.0486 | |||
| Profit Margin | (1.19) % | |||
| Operating Margin | (1.18) % | |||
| Current Valuation | 550.27 M | |||
| Shares Outstanding | 441.01 M | |||
| Price To Book | 1.08 X | |||
| Price To Sales | 2.28 X | |||
| Revenue | 415.86 M | |||
| EBITDA | (324.03 M) | |||
| Cash And Equivalents | 2.96 B | |||
| Cash Per Share | 6.75 X | |||
| Total Debt | 70.78 M | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 10.09 X | |||
| Cash Flow From Operations | (456.92 M) | |||
| Earnings Per Share | (0.13) X | |||
| Total Asset | 5.11 B | |||
About Venus Medtech Performance
By analyzing Venus Medtech's fundamental ratios, stakeholders can gain valuable insights into Venus Medtech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Venus Medtech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Venus Medtech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Venus Medtech Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company was founded in 2009 and is headquartered in Hangzhou, the Peoples Republic of China. Venus Medtech operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 905 people.Things to note about Venus Medtech performance evaluation
Checking the ongoing alerts about Venus Medtech for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Venus Medtech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Venus Medtech generated a negative expected return over the last 90 days | |
| Venus Medtech has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 415.86 M. Net Loss for the year was (373.64 M) with profit before overhead, payroll, taxes, and interest of 324.34 M. | |
| Venus Medtech has accumulated about 2.96 B in cash with (456.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.75, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 22.0% of the company outstanding shares are owned by insiders |
- Analyzing Venus Medtech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Venus Medtech's stock is overvalued or undervalued compared to its peers.
- Examining Venus Medtech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Venus Medtech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Venus Medtech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Venus Medtech's pink sheet. These opinions can provide insight into Venus Medtech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Venus Pink Sheet analysis
When running Venus Medtech's price analysis, check to measure Venus Medtech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Venus Medtech is operating at the current time. Most of Venus Medtech's value examination focuses on studying past and present price action to predict the probability of Venus Medtech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Venus Medtech's price. Additionally, you may evaluate how the addition of Venus Medtech to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |